IVD

The company is developing and validating assays for difficult-to-treat and drug-resistant infectious diseases based primarily on targets, biomarkers, and PCR primers developed at the Translational Genomics Research Institute and Northern Arizona University.

The test, which amplifies and detects methylated Septin9 DNA from patient plasma samples, has been shown to identify a higher proportion of colorectal cancers than Quest Diagnostics' laboratory-developed test, called ColoVantage; as well as CE-marked in vitro diagnostics offered in Europe by Epigenomics and Abbott.

Life Tech officials said that Stokes Bio's microfluidics-based technology platform will enable high-throughput, PCR-based genetic analyses for a variety of applications, particularly in the area of agricultural biology.

Synlab has started offering Epi proColon, Epigenomics' PCR-based blood test for early detection of colorectal cancer, through 55 German sites in its network. In addition, Epigenomics recently raised €33.1 million ($44.2 million) through a combined private and public share offering.

Molecular Detection's Detect-Ready MRSA test; Diatherix Laboratories' GI panel; DNA test for early Lyme disease at Connecticut's Milford Hospital

European customers using or planning to use the 7500 Fast Dx instrument to develop in vitro diagnostic content now have a "much easier" path when submitting a complete IVD platform for regulatory approval by European authorities, a Life Tech official said.

Promega's Maxwell 16 IVD System, Norgen Biotek's diagnostic kits

Under the new license with Roche, Biosearch now has the right to manufacture and sell validated kits, including probes, primers, enzymes, and other essential nucleic acid amplification technologies.

AcroMetrix provides molecular and serological diagnostic quality control products to clinical laboratories, blood screening centers, and in vitro diagnostic manufacturers.

The Berlin-based company is planning to market the test in Germany, Switzerland, and Austria. Epigenomics will partner with distributors Abbott Molecular and Quest Diagnostics to launch the test in other European countries, as well as the US.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.